BiotechTube
Novum Pharmaceutical Research Services

Novum Pharmaceutical Research Services

Pittsburgh, United States· Est.
novumprs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $55M

Overview

Novum Pharmaceutical Research Services operates as a key North American brand for Lambda Therapeutic Research, following its acquisition in 2019. With a legacy of over 50 years in high-quality research, Novum delivers integrated, turnkey clinical trial management with a strong focus on regulatory success, boasting numerous FDA approvals. The company differentiates itself through vast therapeutic expertise, an impeccable regulatory track record, and a fully integrated service portfolio that includes a dedicated Clinical Pharmacology Research Unit and bioanalytical capabilities.

Drug DeliverySmall Molecules

Technology Platform

Integrated full-service CRO platform with owned Clinical Pharmacology Research Unit (Phase I), bioanalytical labs, and global clinical trial management capabilities for early to late-phase studies.

Funding History

2
Total raised:$55M
Debt$15M
Series B$40M

Opportunities

Growing demand for CRO services in complex drug delivery (inhalation, transdermal) and biosimilar development aligns with Novum's specialized expertise.
The expansion of the biotech sector creates a need for full-service, regulatory-savvy partners like Novum to guide smaller companies from early development to submission.

Risk Factors

Faces intense competition from larger global CROs and niche players, which could pressure pricing.
Operational risks, including patient recruitment delays, site performance issues, or regulatory compliance failures, could damage its reputation and financial performance.
The business is also subject to cyclical swings in biopharma R&D spending.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large players like IQVIA, LabCorp, and Parexel, as well as numerous mid-size and niche CROs. Differentiates through deep expertise in complex dosage forms, a strong track record in regulatory submissions (ANDA/505(b)(2)), and an integrated service model from Phase I to Phase IV.

More companies in Digital Health & Biotech SaaS →More companies in United States →